Walking the Double Bottom-Line
PaxVax Preps Cholera Vaccine For Phase III; H5N1 for Phase II
By Trista Morrison
Tuesday, March 20, 2012
PaxVax Corp. is gearing up for Phase III trials with PXVX-0200, a fast-acting cholera vaccine designed to target both developing countries and the more lucrative travelers' market exemplifying PaxVax's "double bottom-line" mission, according to the firm's executive vice president and chief operating officer, Nima Farzan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.